Weekly Signal 15: Restoring Minds, Reshaping Rights

Table of Contents

• Weekly Signal

• Complete our community challenge

• Refer a Neurohacker

• Help us Improve

🧠 Weekly Signal

Restoring Minds, Reshaping Rights

Neurotechnology News | July 5 – 11, 2025

Let's cut through the noise this week!

From real-time BCI speech and epilepsy cell therapies to mental privacy policy debates—this week captures both the promise and pressure of a rapidly advancing neurotech frontier.

🧠 SCIENCE & CLINICAL TRIALS

🟢Cell Therapy for Epilepsy Shows Durable Engraftment

Published: July 11, 2025

Sources: Neurona Therapeutics / Biospace

Neurona Therapeutics published a peer-reviewed study on NRTX-1001, a regenerative interneuron cell therapy for mesial temporal lobe epilepsy. The treatment showed long-lasting GABAergic engraftment in preclinical models and will begin Phase 3 trials later this year.

💡 Big Picture: This could mark a turning point in epilepsy care by offering a regenerative, long-term solution for patients unresponsive to medication.

💼 INDUSTRY & STARTUPS

🟢 China Launches First Invasive BCI Trial Using NeuroXess NEO

Published: July 8, 2025

Sources: Nature / NeuroXess

China has begun its first invasive BCI trial with NeuroXess’ wireless NEO implant. In early results, the chip enabled real-time Mandarin speech decoding in a paralyzed patient at 50 words per minute—via a minimally invasive magnetic actuation design.

💡 Big Picture: China’s rapid entry into invasive BCIs intensifies the global race—and showcases a less invasive path to scalable human–machine interfaces.

🟢 ALS Community Petitions FDA for NurOwn Approval

Published: July 8, 2025

Sources: Brainstorm / BioSpace

A group of ALS patients and advocates have submitted a formal petition asking the U.S. Food and Drug Administration (FDA) to take another look at a treatment called NurOwn—a stem cell therapy developed by BrainStorm Therapeutics. New long-term data shows that some patients treated with NurOwn survived for five years or more, which is well above the average life expectancy after an ALS diagnosis.

Although the FDA has previously been cautious about approving NurOwn due to mixed clinical trial results, this new survival data is giving patients renewed hope. In response, BrainStorm is launching a new Phase IIIb clinical trial starting this summer to further test the treatment and potentially support future approval.

💡 Big Picture: Community momentum, paired with robust long-term outcomes, could reignite regulatory traction for a long-controversial ALS treatment.

🏛️ POLICY & ETHICS

🟢 EU Urged to Regulate Consumer Neurotech Devices

Published: July 7, 2025

Sources: TechPolicy.Press

A policy article by Dr. Virginia Mahieu warns of regulatory blind spots in Europe’s approach to consumer BCIs and neurowearables. She calls for urgent updates to protect mental privacy, data ownership, and algorithmic transparency.

💡 Big Picture: Europe’s regulatory lag could leave millions vulnerable to neural data misuse as consumer neurotech floods the market.

🟢 Cerebralink: Mental Privacy Should Be a Human Right

Published: July 1, 2025 (widely cited this week)

Sources: Cerebralink

Neuroethics group Cerebralink released a report calling for legal frameworks that treat mental privacy as a fundamental human right. They argue for stronger safeguards around cognitive liberty, especially as BCIs influence personality, mood, and thought.

💡 Big Picture: Neurotech’s growth is outpacing legal protections—raising existential questions about the boundaries of mind and machine.

🎯 Community Challenge

Ready to take neurotech to the next level? Share your insights, projects, ideas, our upcoming list of NeuroHacks, or your own groundbreaking work—and watch the inspiration ripple across the community!

How to Participate

1. Create a Post
   Show us what you’re working on—DIY projects, research breakthroughs, or even your latest neurotech musings.

2. Use #NeuroCircuitChallenge
   This helps your ideas reach fellow enthusiasts and potential collaborators.

3. Mention @HackTheNeuron
   Tag us directly in your post so we never miss your entry—and we’ll amplify your work across our entire NeuroCircuit community!

Why Join?

• Boost Your Reach: Tap into a niche but fast-growing community for extra visibility.

• Build Your Network: Connect with researchers, developers, and curious tinkerers who share your passion.

• Shape Neurotech’s Future: Your project or insight could spark the next big breakthrough—or inspire someone else’s.

We can’t wait to see your creativity in action! Fire up X, LinkedIn, Facebook, Instagram, or TikTok, and spread the word. Let’s spark innovation together!

🚀Recruit More Neurohackers

Your referrals are the engine that drives our community forward. Share your unique referral link with friends, colleagues, or fellow neurotech enthusiasts—and watch us grow together!

• Spread the Word: Copy your personal referral link and post it on social, forums, or in emails.

• Unlock Exclusive Perks: Every friend who subscribes through your link brings you closer to special rewards—insider insights, private Discord access, early project previews, and more.

• Be the Catalyst: The more you share, the stronger our network becomes. Help us build the ultimate neurotech hub—one referral at a time!

✍️Help Us Improve

Your input is what will make The NeuroCircuit and Hack The Neuron better. Let us know what you’d like more of—and what we can do differently.

• Share Your Ideas: Tell us which topics, features, or formats you’d love to see next.

• Spot the Gaps: Let us know if anything’s missing or unclear in our content and community tools.

• Shape the Experience: Whether it’s new challenges, tutorials, or platform features, your suggestions guide our roadmap.